I 
112TH CONGRESS 
2D SESSION 
H. R. 6033 
To provide for research and education to improve screening, detection and 
diagnosis of prostate cancer. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 27, 2012 
Mr. CUMMINGS (for himself, Mr. BURTON of Indiana, Mr. CARSON of Indiana, 
Mrs. CHRISTENSEN, Ms. CLARKE of New York, Mr. CLAY, Mr. JACKSON 
of Illinois, and Mr. RANGEL) introduced the following bill; which was re-
ferred to the Committee on Energy and Commerce 
A BILL 
To provide for research and education to improve screening, 
detection and diagnosis of prostate cancer. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Prostate Cancer Detec-
tion Research and Education Act’’. 
SEC. 2. PLAN TO DEVELOP AND VALIDATE A TEST OR 
TESTS FOR PROSTATE CANCER. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services (referred to in this Act as the ‘‘Sec-
VerDate Mar 15 2010 
03:58 Jul 03, 2012
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6033.IH
H6033
smartinez on DSK6TPTVN1PROD with BILLS
retary’’), acting through the Director of the National In-
stitutes of Health, shall establish an advisory council on 
prostate cancer (referred to in this Act as the ‘‘advisory 
council’’) to draft a plan for the development and valida-
tion of an accurate test or tests, such as biomarkers or 
imaging, to detect and diagnose prostate cancer. 
(b) ADVISORY COUNCIL.— 
(1) MEMBERSHIP.— 
(A) FEDERAL
MEMBERS.—The advisory 
council shall be comprised of the following ex-
perts: 
(i) A designee of the Centers for Dis-
ease Control and Prevention. 
(ii) A designee of the Centers for 
Medicare & Medicaid Services. 
(iii) A designee of the Office of the 
Director of the National Cancer Institute. 
(iv) A designee of the Director of the 
Department of Defense Congressionally 
Directed Medical Research Program. 
(v) A designee of the Director of the 
National Institute of Biomedical Imaging 
and Bioengineering. 
VerDate Mar 15 2010 
03:58 Jul 03, 2012
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6033.IH
H6033
smartinez on DSK6TPTVN1PROD with BILLS
(vi) A designee of the Director of the 
National Institute of General Medical 
Sciences. 
(vii) A designee of the Director of the 
National Institute on Minority Health and 
Health Disparities. 
(viii) A designee of the Office of the 
Director of the National Institutes of 
Health. 
(ix) A designee of the Food and Drug 
Administration. 
(x) A designee of the Agency for 
Healthcare Research and Quality. 
(xi) A designee of the Director of the 
Telemedicine and Advanced Technology 
Research Center of the Department of De-
fense. 
(B) NON-FEDERAL
MEMBERS.—In addi-
tion to the members described in subparagraph 
(A), the advisory council shall include 8 expert 
members from outside the Federal Government 
to be appointed by the Secretary, which shall 
include— 
(i) 2 prostate cancer patient advo-
cates; 
VerDate Mar 15 2010 
03:58 Jul 03, 2012
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6033.IH
H6033
smartinez on DSK6TPTVN1PROD with BILLS
(ii) 2 health care providers with a 
range of expertise and experience in pros-
tate cancer; and 
(iii) 4 leading researchers with pros-
tate cancer-related expertise in a range of 
clinical disciplines. 
(2) MEETINGS.—The advisory council shall 
meet quarterly and such meetings shall be open to 
the public. 
(3) ADVICE.—The advisory council shall advise 
the Secretary, or the Secretary’s designee. 
(4) ANNUAL REPORT.—Not later than 1 year 
after the date of enactment of this Act, the advisory 
council shall provide to the Secretary, or the Sec-
retary’s designee and Congress— 
(A) an initial evaluation of all federally 
funded efforts in prostate cancer research relat-
ing to the development and validation of an ac-
curate test or tests to detect and diagnose pros-
tate cancer; 
(B) a plan for the development and valida-
tion of a reliable test or tests for the detection 
and accurate diagnosis of prostate cancer; and 
(C) a set of standards for prostate cancer 
screening, developed in coordination with the 
VerDate Mar 15 2010 
03:58 Jul 03, 2012
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6033.IH
H6033
smartinez on DSK6TPTVN1PROD with BILLS
United States Preventive Services Task Force, 
to ensure that any tools for screening, detec-
tion, and diagnosis developed in accordance 
with the plan under subparagraph (B) will meet 
the requirements of the Task Force for rec-
ommendation as a proven preventive or diag-
nostic service. 
(5) TERMINATION.—The advisory council shall 
terminate on December 31, 2016. 
(c) FUNDING.—The Secretary may make available 
$1,000,000 from amounts appropriated to the National 
Institutes of Health for each of fiscal years 2013 through 
2017 to carry out this section. 
SEC. 3. COORDINATION AND INTENSIFICATION OF PROS-
TATE CANCER RESEARCH. 
(a) IN GENERAL.—The Director of the National In-
stitutes of Health, in consultation with the Secretary of 
Defense, shall coordinate and intensify research in accord-
ance with the plan developed under section 2(b)(4)(B), 
with particular attention provided to leveraging existing 
research to develop and validate a test or tests, such as 
biomarkers or imaging, to detect and accurately diagnose 
prostate cancer in order to improve quality of life for mil-
lions of Americans, and decrease health care system costs. 
VerDate Mar 15 2010 
03:58 Jul 03, 2012
Jkt 019200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H6033.IH
H6033
smartinez on DSK6TPTVN1PROD with BILLS
(b) FUNDING.—The Secretary may make available 
$30,000,000 from amounts appropriated to the National 
Institutes of Health for each of fiscal years 2014 through 
2018 to carry out this section. 
SEC. 4. PUBLIC AWARENESS AND EDUCATION CAMPAIGN. 
(a) NATIONAL CAMPAIGN.—The Secretary, in coordi-
nation with the Director of the National Institutes of 
Health and the Director of the Centers for Disease Con-
trol and Prevention, shall carry out a national campaign 
to increase the awareness and knowledge of prostate can-
cer. 
(b) REQUIREMENTS.—The national campaign con-
ducted under subsection (a) shall include— 
(1) roles for the National Cancer Institute, the 
National Institute on Minority Health and Health 
Disparities, the Office on Minority Health of the De-
partment of Health and Human Services, and the 
Office of Minority Health of the Centers for Disease 
Control and Prevention; and 
(2) the development and distribution of written 
educational materials, and the development and 
placing of public service announcements, that are in-
tended to encourage men to seek prostate cancer 
screening when symptoms are present, when they 
VerDate Mar 15 2010 
03:58 Jul 03, 2012
Jkt 019200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H6033.IH
H6033
smartinez on DSK6TPTVN1PROD with BILLS
have a family history of prostate cancer, or if they 
belong to a high-risk population. 
(c) RACIAL DISPARITIES.—In developing the national 
campaign under subsection (a), the Secretary shall recog-
nize and address— 
(1) the racial disparities in the incidences of 
prostate cancer and mortality rates with respect to 
such disease; and 
(2) any barriers in access to patient care and 
participation in clinical trials that are specific to ra-
cial minorities. 
(d) GRANTS.—The Secretary shall establish a pro-
gram to award grants to nonprofit private entities to en-
able such entities to test alternative outreach and edu-
cation strategies to increase the awareness and knowledge 
of Americans with respect to prostate cancer. 
(e) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to carry out this section, 
$5,000,000 for each of fiscal years 2013 through 2017. 
Æ 
VerDate Mar 15 2010 
03:58 Jul 03, 2012
Jkt 019200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6301
E:\BILLS\H6033.IH
H6033
smartinez on DSK6TPTVN1PROD with BILLS